

Control of Diastereoselectivity for Iridium-catalyzed Allylation of a Prochiral Nucleophile with a Phosphate Counterion

Wenyong Chen and John F. Hartwig*

Department of Chemistry, University of California, Berkeley, California, 94720, United States

Supporting Information

Table of Contents

General Experimental Details	S-1
General Procedure for Evaluation of Reaction Conditions	S-2
Procedure for the Synthesis of DBCOT	S-3
Procedure for the Synthesis of 2c	S-3
General Procedure for Ir-Catalyzed Allylation of Azlactones	S-4
Procedure for the Synthesis of 6e	S-19
References	S-22
¹ H, ¹³ C and ³¹ P NMR Spectra for All New Compounds	S-23

General Experimental Details

All air-sensitive manipulations were conducted under an inert atmosphere in a nitrogen-filled glovebox or by standard Schlenk techniques. DCM, toluene, THF were degassed by purging with argon for 15 minutes and dried with a solvent purification system containing a one-meter column of activated alumina. Cinnamyl alcohol, 4-nitrocinnamyl alcohol, 4-methoxybenzaldehyde, 4-fluorobenzaldehyde, 3-fluorobenzaldehyde and 4-chlorobenzaldehyde were purchased from Sigma-Aldrich and used without further purification. Vinylmagnesium chloride was purchased as a 1.6 M solution in THF from Sigma-Aldrich. Azlactones were prepared according to literature procedures.¹ All the allylic carbonates and phosphates were prepared according to literature procedures.² The racemic samples were prepared by using racemic catalyst.


[Ir(cod)Cl]₂ was obtained from Johnson-Matthey and used without further purification. Phosphoramidite ligands **1** were synthesized according to literature procedures.³ [Ir(COD)(κ^2 -**1**)(ethylene)] (**1**) was prepared according to literature procedures.⁴ GC analyses were obtained on an Agilent 6890 GC equipped with an HP-5 column (25 m x 0.20 mm ID x 0.33 m film) and an FID detector. HPLC analyses were carried out on a Waters chromatography system (1525 binary pump, 717+ autosampler, 2487 dual wavelength detector) with using chiral stationary columns (0.46 cm x 25 cm) from Daicel. Optical rotations were measured on a Perkin Elmer 241 Automatic Polarimeter. High resolution mass spectra and elemental analyses were obtained via the Micro-Mass/Analytical Facility operated by the College of Chemistry, University of

California, Berkeley. NMR spectra were acquired on Bruker AVQ-400, AVB-400, DRX 500, and AV-600 spectrometers. Chemical shifts were reported in ppm relative to a residual solvent peak ($\text{CDCl}_3 = 7.26$ ppm for ^1H and 77.00 ppm for ^{13}C). Coupling constants were reported in hertz. Flash column chromatography was performed on Silicyle Silica-P silica gel. Products were visualized on TLC plates by UV or by staining with KMnO_4 .

General Procedure for Evaluation of Reaction Conditions

In a nitrogen-filled dry-box, the cinnamyl carbonate (0.250 mmol, 1.00 equiv), $[\text{Ir}(\text{cod})\text{Cl}]_2$ (0.0050 mmol, 0.0200 equiv), ligand **1** (0.0100 mmol, 0.0400 equiv), AgX (0.0200 mmol, 0.0800 equiv) and toluene (0.25 mL) were added to a 1-dram vial. The mixture was stirred for 20 min before azlactone **3** (0.550 mmol, 2.20 equiv) and 3 Å MS (50 mg) were added. The vial was sealed with a PTFE/silicone-lined septum cap, removed from the dry-box, and stirred at room temperature for 8 h. The reaction progress was monitored by TLC. When the reaction was judged to be complete, the solution was filtered through a 0.5 inch plug of silica gel (eluting with EtOAc) to remove the solid. The crude reaction mixture was concentrated under reduced pressure. CDCl_3 (0.7-0.8 mL) was added to dissolve the crude reaction mixture, and mesitylene (23 μL) was added as an internal standard. The diastereoselectivity was then determined by ^1H NMR spectroscopy. After this analysis, the crude reaction mixture was purified by flash column silica gel chromatography (eluting with hexanes: EtOAc , 10:1 to 6:1) to yield the product.

Table 1. Evaluation of Ligand, Leaving Group, Solvent and Counterion Effect on the Ir-Catalyzed Allylation of azlactone **3^a**




Entry	ligand	LG	Solvent	AgX	Yield(%) ^b	dr ^c	ee(%) ^d
1 ^e	1	OCOOMe	toluene	AgBF_4	31	7:1	98
2	1	OCOOMe	toluene	2a	83	8:1	98
3	1	OCOOMe	toluene	2b	87	>20:1	98
4 ^f	1	OCOOMe	toluene	2b	57	>20:1	98
5 ^g	1	OCOOMe	toluene	2b	70	>20:1	98
6	ent- 1	OCOOMe	toluene	2b	88	20:1	-98
7	1	OCOOMe	toluene	2c	89(87)	>20:1	98
8	1	OCOOMe	toluene	2d	81	18:1	98
9	1	OCOOMe	THF	2b	90	6:1	92

10	1	OCOOMe	dioxane	2b	62	6:1	97
11	1	OCOOMe	DCM	2b	52	5:1	92
12	1	OBoc	Toluene	2c	58	14:1	95
13	1	OTroc	Toluene	2c	85	4:1	-
14	1	OPO(OEt) ₂	Toluene	2c	36	2:1	-


^aSee the Supporting Information (SI) for experimental details. Absolute configuration of the allylation product was determined by chemical correlation. ^bDetermined by ¹H NMR analysis with mesitylene as the internal standard. Numbers in parentheses correspond to isolated yield. ^cDetermined by ¹H NMR analysis of crude reaction mixtures. ^dDetermined by chiral HPLC analysis of the major diastereomer. ^e90% conversion of cinnamyl carbonate. ^f4 mol % **2b** was used. 64% conversion of cinnamyl carbonate. ^gWithout molecular sieves. 80% conversion of cinnamyl carbonate.

Procedure for the Synthesis of DBCOT



To the 20 mL absolute ethanol solution of **S1**⁵ (782 mg, 1.00 equiv, 3.55 mmol) and TsNNH₂ (727mg, 1.10 equiv, 3.91 mmol) was added 10 μ L concentrated hydrochloric acid. The solution was stirred for 12 h. After the reaction was complete, the white precipitate formed was collected by filtration. The precipitate was washed with 1 mL ice-cold ethanol, and was then dried in vaccuum to yield white powder **S2** in 76% yield (1.05 g). In a glovebox, **S2** (500 mg, 1.00 equiv, 1.29 mmol) was dissolved in 8 mL THF and 24 mL of ether in a round bottom flask. BuLi (2.42 mL, 1.6 M in hexane, 3.0 equiv, 3.9 mmol) was added to the solution. During this time, the reaction mixture changed to a dark red solution. When the reaction was determined to be complete, according to TLC, in 1 h, the flask was removed from glovebox. The reaction mixture became light yellow when the reaction was quenched with 5 mL saturated NH₄Cl solution. The mixture was poured into a separatory funnel, and the layers were separated. The aqueous layer was extracted by EtOAc (2 x 5 mL), and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated. Flash chromatography over silica gel with hexanes afforded **S3** in 83% (215 mg) as a white powder. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (dd, *J* = 5.5, 2.5 Hz, 1H), 7.07 (d, *J* = 3.2 Hz, 1H), 6.76 (s, 1H).

Procedure for the Synthesis of **2c**




To the 3 mL ACN/DCM (1/1) solution of **4**⁶ (2 g, 1.00 equiv, 4.24 mmol) and was added Ag₂CO₃ (643 mg, 0.55 equiv, 2.33 mmol). The solution was stirred for 2 h. After the reaction was complete, the precipitate was filtered. The solvent was removed to afford **2c** in 95% (2.33 g) yield as an off-white powder. ¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, *J* = 1.3 Hz, 2H), 7.18 (d, *J* = 2.4 Hz, 2H), 1.55 (s, 18H), 1.33 (s, 18H). ¹³C NMR (126 MHz, CDCl₃) δ 146.9, 139.60, 139.57, 130.7, 126.5, 124.7, 35.5, 34.6, 31.52, 31.46. Anal. Calcd. for C₂₈H₄₀AgO₄P·CH₃CN: C, 58.07; H, 6.98; N, 2.26; found: C, 58.16; H, 6.98; N, 1.96.


General Procedure for Ir-catalyzed Allylation of Azlactones

In a nitrogen-filled dry-box, the allylic carbonate (0.250 mmol, 1.00 equiv), [Ir(cod)Cl]₂ (0.0050 mmol, 0.0200 equiv), **1** (0.0100 mmol, 0.0400 equiv), **2c** (0.0200 mmol, 0.0800 equiv) and toluene (0.25 mL) were added to a 1-dram vial. The mixture was stirred for 20 min before azlactone (0.550 mmol, 2.20 equiv) and 3 Å MS (50 mg) were added. The vial was sealed with a PTFE/silicone-lined septum cap, removed from the dry-box, and stirred at room temperature for 1-24 h. The reaction progress was monitored by TLC. When the reaction was judged to be complete, the solution was filtered through a 0.5 inch plug of silica gel (eluting with EtOAc) to remove the solid. The crude reaction mixture was concentrated under reduced pressure. CDCl₃ (0.7-0.8 mL) was added to dissolve the crude reaction mixture. The diastereoselectivity was then determined by ¹H NMR spectroscopy. After this analysis, the crude reaction mixture was purified by flash column silica gel chromatography (eluting with hexanes:EtOAc, 16:1 to 3:1) to yield the product.


(S)-4-methyl-2-phenyl-4-((R)-1-phenylallyl)oxazol-5(4H)-one



Prepared according to the general procedure using cinnamyl methyl carbonate (48.0 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 87% yield (63.3 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 28.5 min (major); t_R 21.4 min (minor) [(Chiralcel OJ-H) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98%. [α]_D²⁵ = -72.3° (c 0.7, CH₂Cl₂). ¹H NMR (600 MHz, CDCl₃) δ 8.02 (d, *J* = 8.0 Hz, 2H), 7.58 (t, *J* = 7.0 Hz, 1H), 7.52-7.45 (m, 4H), 7.35 (t, *J* = 7.4 Hz, 2H), 7.30 – 7.23 (m, 1H), 6.03 (dt, *J* = 16.8, 9.6 Hz, 1H), 5.21 (d, *J* = 16.9 Hz, 1H), 5.11 (d, *J* = 10.1 Hz, 1H), 3.71 (d, *J* = 9.5 Hz, 1H), 1.37 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 180.6, 159.8, 138.4, 135.5, 132.6, 129.1, 128.7, 128.5, 128.0, 127.4, 125.8, 118.9, 73.5, 57.5, 22.4.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	22.374	29768389	50.54	291769	63.82
2	30.904	29129743	49.46	165412	36.18




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	21.274	647490	0.91	8750	2.17
2	28.504	70318582	99.09	395152	97.83

(S)-4-((R)-1-(4-fluorophenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 4-fluorocinnamyl methyl carbonate (52.5 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 85% yield (65.7 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 15.1 min (major); t_R 17.0 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 99.5:0.5, 0.5 mL/min] to be 98%. $[\alpha]_D^{25} = -98.0^\circ$ (c 0.4, CH₂Cl₂). ¹H NMR (600 MHz, CDCl₃) δ 8.01 (d, J = 7.8 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.50 (t, J = 7.3 Hz, 2H), 7.47 – 7.38 (m, 2H), 7.03 (t, J = 8.1 Hz, 2H), 5.97 (dt, J = 16.8, 10.2 Hz, 1H), 5.18 (d, J = 16.9 Hz, 1H), 5.11 (d, J = 10.1 Hz, 1H), 3.69 (d, J = 9.4 Hz, 1H), 1.34 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 180.4, 162.1 (d, J = 246 Hz), 159.9, 135.3, 134.1(d, J = 3.8 Hz), 132.7, 130.7 (d, J = 7.9 Hz), 128.7, 127.9, 125.7, 119.0, 115.3 (d, J = 21.2 Hz), 73.3, 56.6, 22.4.





	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	15.239	41408107	48.10	1575794	55.47
2	16.778	44681139	51.90	1264908	44.53

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	15.097	28034297	99.09	1225476	99.01
2	16.983	258300	0.91	12223	0.99

(S)-4-((R)-1-(4-chlorophenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 4-chlorocinnamyl methyl carbonate (56.6 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol,), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as white wax in 84% yield (68.3 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_{R} 4.43 min (major); t_{R} 4.78 min (minor) [(Chiralpak AD-H) hexane/*i*-PrOH, 95:5, 1.0 mL/min] to be 99%. $[\alpha]_D^{25} = -121^\circ$ (c 2.5, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.09 – 7.96 (m, 2H), 7.59 (t, *J* = 7.4 Hz, 1H), 7.50 (t, *J* = 7.7 Hz, 2H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 5.94 (dt, *J* = 17.0, 9.8 Hz, 1H), 5.19 (d, *J* = 16.9 Hz, 1H), 5.11 (d, *J* = 10.2 Hz, 1H), 3.68 (d, *J* = 9.4 Hz, 1H), 1.34 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) 180.4, 160.1, 136.9, 135.1, 133.3, 132.9, 130.5, 128.8, 128.7, 128.0, 125.7, 119.3, 73.3, 56.8, 22.5.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.431	14823878	49.33	1842141	50.40
2	4.801	15229299	50.67	1813217	49.60

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.428	34020501	99.44	2405438	98.92
2	4.776	192890	0.56	26207	1.08

(S)-4-((R)-1-(4-methoxyphenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 4-methoxycinnamyl methyl carbonate (55.5 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 68% yield (54.6 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 6.88 min (major); t_R 10.30 min (minor) [(Chiraldak AD-H) hexane/*i*-PrOH, 99:1, 1.0 mL/min] to be >99%. $[\alpha]_D^{25} = -105^\circ$ (c 1.7, CH₂Cl₂). ¹H NMR (600 MHz, CDCl₃) δ 8.02 (d, *J* = 7.7 Hz, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 7.38 (d, *J* = 8.5 Hz, 2H), 6.88 (d, *J* = 8.5 Hz, 2H), 5.99 (dt, *J* = 17.1, 9.8 Hz, 1H), 5.18 (d, *J* = 16.9 Hz, 1H), 5.08 (d, *J* = 10.1 Hz, 1H), 3.79 (s, 3H), 3.66 (d, *J* = 9.4 Hz, 1H), 1.35 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 180.7, 159.8, 158.8, 135.7, 132.6, 130.4, 130.1, 128.7, 127.9, 125.9, 118.5, 113.8, 73.6, 56.7, 55.2, 22.4.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	6.822	25245277	49.73	601903	57.82
2	10.302	25517071	50.27	439029	42.18

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	6.883	56108477	99.67	1296065	99.67
2	10.627	184042	0.33	4307	0.33

(S)-4-methyl-2-phenyl-4-((R)-1-(4-(trifluoromethyl)phenyl)allyl)oxazol-5(4H)-one




Prepared according to the general procedure using 4-trifluoromethylcinnamyl methyl carbonate (65.0 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), $[\text{Ir}(\text{cod})\text{Cl}]_2$ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 82% yield (73.6 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_{R} 5.74 min (major); t_{R} 6.13 min (minor) [(Chiralpak AD-H) hexane/*i*-PrOH, 99.5:0.5, 1.0 mL/min] to be 94%. $[\alpha]_{\text{D}}^{25} = -105^\circ$ (c 2.0, CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3) δ 8.12 – 7.95 (m, 2H), 7.69 – 7.56 (m, 5H), 7.51 (t, $J = 7.7$ Hz, 2H), 5.95 (dt, $J = 17.0, 9.8$ Hz, 1H), 5.22 (d, $J = 16.9$ Hz, 1H), 5.13 (dd, $J = 10.2, 0.8$ Hz, 1H), 3.77 (d, $J = 9.4$ Hz, 1H), 1.34 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 180.2, 160.2, 142.5, 134.8, 132.9, 129.62, 129.63 (q, $J = 32.6$ Hz), 128.9, 128.0, 125.6, 125.5 (q, $J = 3.78$ Hz), 124.1 (q, $J = 272$ Hz), 119.8, 73.2, 57.1, 22.4. HRMS (ESI) Calcd. for $\text{C}_{20}\text{H}_{16}\text{NO}_2\text{F}_3$ ($[\text{M}]^+$): 359.1133. Found: 359.1132.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	5.855	20743189	47.47	1923289	50.75
2	6.269	22950009	52.53	1866143	49.25

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	5.773	21623668	96.98	2022752	94.70
2	6.128	674481	3.02	113201	5.30

(S)-4-methyl-4-((R)-1-(4-nitrophenyl)allyl)-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 4-nitrocinnamyl methyl carbonate (59.3 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol,), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 6:1 to 3:1) to give the title compound as colorless oil in 83% yield (69.7 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 8.76 min (major); t_R 9.91 min (minor) [(Chiralpak AD-H) hexane/*i*-PrOH, 98:2, 1.0 mL/min] to be 84%. $[\alpha]_D^{25} = -185^\circ$ (c 1.5, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.21 (d, *J* = 8.8 Hz, 2H), 8.07 – 7.96 (m, 2H), 7.67 (d, *J* = 8.7 Hz, 2H), 7.60 (t, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 2H), 5.94 (dt, *J* = 16.9, 9.8 Hz, 1H), 5.23 (d, *J* = 16.9 Hz, 1H), 5.16 (d, *J* = 10.2 Hz, 1H), 3.83 (d, *J* = 9.4 Hz, 1H), 1.35 (s, 4H). ¹³C NMR (126 MHz, CDCl₃) δ 179.9, 160.4, 147.3, 146.0, 134.2, 133.1, 130.2, 128.9, 128.0, 125.4, 123.7, 120.3, 73.0, 57.0, 22.5. HRMS (ESI) Calcd. for C₁₉H₁₇N₂O₄ ([M+H]⁺): 337.1188. Found: 337.1189.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	8.823	11489593	48.95	688510	50.16
2	9.921	11983036	51.05	684230	49.84

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	8.761	33909565	91.42	1675712	90.15
2	9.913	3183306	8.58	183090	9.85

(S)-4-((R)-1-(3-fluorophenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 3-fluorocinnamyl methyl carbonate (52.5 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 96% yield (74.2 mg). The enantiomeric excess was determined by HPLC analysis of methanolysis product (254 nm, 25 °C) t_R 9.97 min (major); t_R 13.08 min (minor) [(Chiralpak AS-H) hexane/*i*-PrOH, 98:2, 1.0 mL/min] to be >99%. $[\alpha]_D^{25} = -82.7^\circ$ (c 2.5, CH₂Cl₂). ¹H NMR (600 MHz, CDCl₃) δ 8.03 (d, *J* = 7.3 Hz, 2H), 7.59 (t, *J* = 7.2 Hz, 1H), 7.51 (t, *J* = 7.1 Hz, 2H), 7.37 – 7.25 (m, 2H), 7.22 (d, *J* = 7.4 Hz, 1H), 6.98 (t, *J* = 8.2 Hz, 1H), 6.06 – 5.82 (dt, *J* = 16.9, 10.0 Hz, 1H), 5.21 (d, *J* = 16.9 Hz, 1H), 5.11 (d, *J* = 10.0 Hz, 1H), 3.70 (d, *J* = 9.2 Hz, 1H), 1.36 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 180.3, 162.7 (d, *J* = 246 Hz), 160.0, 140.8 (d, *J* = 7.1 Hz), 135.0, 132.8, 129.9 (d, *J* = 8.2 Hz), 128.8, 128.0, 125.7, 125.0 (d, *J* = 2.7 Hz), 119.3, 116.0 (d, *J* = 21.9 Hz), 114.3 (d, *J* = 21.1 Hz), 73.3, 57.1, 22.4. HRMS (ESI) Calcd. for C₁₉H₁₆NO₂F ([M]⁺): 309.1165. Found: 309.1166.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	10.012	22290353	51.54	703273	62.86
2	12.378	20954892	48.46	415570	37.14

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	9.971	40784869	99.75	1219811	99.71
2	13.080	101820	0.25	3582	0.29

(S)-4-((R)-1-(2-methoxyphenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using 2-methoxycinnamyl methyl carbonate (55.5 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (7:1 mixture of diastereomers) as colorless oil in 81% yield (65.0 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 4.69 min (major); t_R 5.09 min (minor) [(Chiralcel OD-H) hexane/i-PrOH, 92.5:7.5, 1.0 mL/min] to be 80%. [α]_D²⁵ = -83.9° (c 3.5, CH₂Cl₂). 7:1 diastereomer mixtures ¹H NMR (500 MHz, CDCl₃) δ 8.06 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1H), 7.55-7.48 (m, 2H), 7.27 (dd, J = 10.7, 3.9 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 6.08 – 5.80 (dt, J = 16.9, 10.1 Hz, 1H), 5.24 (d, J = 16.9 Hz, 1H), 5.09 (d, J = 10.1 Hz, 1H), 4.52 (d, J = 9.4 Hz, 1H), 3.88 (s, 3H), 1.39 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 181.0, 159.6, 157.2, 135.6, 132.6, 129.7, 128.7, 128.2, 127.9, 126.7, 126.0, 120.7, 118.9, 110.6, 73.8, 55.5, 47.2, 21.8. HRMS (ESI) Calcd. for C₂₀H₂₀NO₃ ([M+H]⁺): 322.1438. Found: 322.1436.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.818	11137861	50.10	1409785	51.63
2	5.153	11094822	49.90	1320604	48.37

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.776	32613357	90.06	2091786	81.99
2	5.181	3600590	9.94	459408	18.01

(S)-4-((S)-1-(furan-2-yl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using (E)-3-(furan-3-yl)allyl methyl carbonate (45.5 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol,), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (15:1 mixture of diastereomers) as colorless oil in 90% yield (63.2 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 4.46 min (major); t_R 4.73 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 92.5:7.5, 1.0 mL/min] to be 98%. [α]_D²⁵ = -69.0° (c 2.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.02 – 7.96 (m, 2H), 7.63 – 7.53 (m, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.36-7.33 (m, 1H), 6.43 – 6.26 (m, 2H), 6.00 (dt, J = 17.1, 9.8 Hz, 1H), 5.24 (d, J = 17.0 Hz, 1H), 5.19 (dd, J = 10.1, 1.1 Hz, 1H), 3.90 (d, J = 9.4 Hz, 1H), 1.49 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 179.6, 160.2, 151.7, 141.8, 132.6, 132.6, 128.7, 127.9, 125.7, 119.6, 110.3, 107.8, 72.5, 50.9, 22.3. HRMS (ESI) Calcd. for C₁₇H₁₆NO₃ ([M+H]⁺): 282.1130. Found: 282.1121.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.443	19501809	48.26	2051690	50.27
2	4.715	20908536	51.74	2029753	49.73

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	4.462	18390618	98.99	1724947	97.79
2	4.731	187360	1.01	38960	2.21

***tert*-Butyl 3-((R)-1-((S)-4-methyl-5-oxo-2-phenyl-4,5-dihydrooxazol-4-yl)allyl)-1*H*-indole-1-carboxylate**




Prepared according to the general procedure using (E)-*tert*-butyl 3-((methoxycarbonyl)oxy)prop-1-en-1-yl)-1*H*-indole-1-carboxylate (82.8 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4*H*)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (15:1 mixture of diastereomers) as colorless oil in 81% yield (87.1 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 4.46 min (major); t_R 4.73 min (minor) [(Chiralcel OD-H) hexane/*i*-PrOH, 99:1, 1.0 mL/min] to be 95%. $[\alpha]_D^{25} = -71.9^\circ$ (c 3.5, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.15 (br s, 1H), 8.06 (d, *J* = 7.8 Hz, 2H), 7.87 (br s, 1H), 7.77 (d, *J* = 7.6 Hz, 1H), 7.63-7.58 (m, 1H), 7.54-7.48 (m, 2H), 7.37-7.27 (m, 2H), 5.97 (d, *J* = 16.8, 10.1 Hz, 1H), 5.29 (d, *J* = 16.8 Hz, 1H), 5.12 (d, *J* = 10.1 Hz, 1H), 4.08 (d, *J* = 9.2 Hz, 1H), 1.74 (s, 9H), 1.51 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 180.5, 160.0, 149.8, 135.1, 134.7, 132.7, 130.3, 128.8, 128.0, 127.99, 125.7, 124.4, 122.5, 119.6, 119.0, 117.4, 115.2, 83.8, 73.7, 48.1, 28.2, 22.5. HRMS (ESI) Calcd. for C₂₆H₂₇N₂O₄ ([M+H]⁺): 431.1965. Found: 431.1965.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	5.391	36707934	51.06	1274681	54.06
2	6.439	35188871	48.94	1083056	45.94

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	5.431	883566	1.72	42203	2.84
2	6.508	50466422	98.28	1445280	97.16

(S)-4-((R,E)-hexa-1,4-dien-3-yl)-4-methyl-2-phenyloxazol-5(4H)-one




Prepared according to the general procedure using (2E,4E)-hexa-2,4-dien-1-yl methyl carbonate (39.0 mg, 0.250 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (96.3 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (14:1:1 mixture of diastereomers and the linear product) as colorless oil in 83% yield (52.9 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_{R} 9.89 min (major); t_{R} 13.36 min (minor) [(Chiralpak AS-H) hexane/*i*-PrOH, 98:2, 0.8 mL/min] to be 94%. $[\alpha]_D^{25} = -4.5^\circ$ (c 2.2, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, J = 7.5 Hz, 2H), 7.62–7.57 (m, 1H), 7.55 – 7.47 (m, 2H), 5.77 – 5.61 (m, 2H), 5.63 – 5.50 (m, 1H), 5.17 (d, J = 17.7 Hz, 1H), 5.09 (dd, J = 10.2, 1.1 Hz, 1H), 3.12 (t, J = 8.6 Hz, 1H), 1.74 (d, J = 6.0 Hz, 3H), 1.49 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 180.4, 159.9, 134.9, 132.6, 130.1, 128.7, 127.9, 126.9, 125.9, 118.3, 72.6, 54.7, 22.2, 18.1. HRMS (ESI) Calcd. for C₁₆H₁₈NO₂ ([M+H]⁺): 256.1338. Found: 256.1334.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	9.609	21249948	53.13	540097	58.46
2	12.657	18749532	46.87	383838	41.54

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	9.894	29386639	97.43	778916	97.72
2	13.359	775744	2.57	18176	2.28

(S)-4-benzyl-2-phenyl-4-((R)-1-phenylallyl)oxazol-5(4H)-one




Prepared according to the general procedure using cinnamyl methyl carbonate (48.0 mg, 0.250 mmol), 4-benzyl-2-phenyloxazol-5(4H)-one (138 mg, 0.550 mmol), $[\text{Ir}(\text{cod})\text{Cl}]_2$ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (12:1 mixture of diastereomers) as colorless oil in 83% yield (76.2 mg). The enantiomeric excess was determined by HPLC analysis of methanolysis product (254 nm, 25 °C) t_R 12.62 min (major); t_R 17.25 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 95:5, 1.0 mL/min] to be >99%. $[\alpha]_D^{25} = -305^\circ$ (c 0.6, CH_2Cl_2). ^1H NMR (600 MHz, CDCl_3) δ 7.85 (d, $J = 7.9$ Hz, 2H), 7.58 (d, $J = 7.7$ Hz, 2H), 7.52 (t, $J = 7.3$ Hz, 1H), 7.46 – 7.36 (m, 4H), 7.31 (t, $J = 7.2$ Hz, 1H), 7.13 – 7.01 (m, 5H), 6.08 (d, $J = 16.9, 10.1$ Hz, 1H), 5.25 (d, $J = 16.9$ Hz, 1H), 5.13 (d, $J = 10.1$ Hz, 1H), 3.91 (d, $J = 9.4$ Hz, 1H), 3.10 (d, $J = 13.5$ Hz, 1H), 2.93 (d, $J = 13.5$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 179.3, 159.8, 138.5, 135.6, 134.3, 132.4, 130.18, 130.12, 129.2, 128.5, 127.9, 127.8, 127.4, 127.0, 125.6, 118.9, 78.7, 57.4, 42.0.




	RT (min)	Area (μ V*sec)	% Area	Height (μ V)	% Height
1	12.681	19454968	53.42	921431	57.48
2	17.255	16961458	46.58	681720	42.52

	RT (min)	Area (μ V*sec)	% Area	Height (μ V)	% Height
1	12.630	30002840	99.40	1321059	99.39
2	17.170	182344	0.60	8129	0.61

(S)-4-benzyl-2-phenyl-4-((R)-1-phenylallyl)oxazol-5(4H)-one




Prepared according to the general procedure using cinnamyl methyl carbonate (48.0 mg, 0.250 mmol), 4-*iso*-butyl-2-phenyloxazol-5(4H)-one (119 mg, 0.550 mmol), [Ir(cod)Cl]₂ (3.36 mg, 0.0050 mmol,), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound (14:1 mixture of diastereomers) as colorless oil in 84% yield (76.2 mg). The enantiomeric excess was determined by HPLC analysis of methanolysis product (254 nm, 25 °C) t_R 8.63 min (major); t_R 11.65 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 95:5, 1.0 mL/min] to be 98%. $[\alpha]_D^{25} = -110^\circ$ (c 2.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, J = 7.3 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.44 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.27 (dd, J = 13.8, 6.5 Hz, 1H), 6.07 (dt, J = 17.0, 9.9 Hz, 1H), 5.22 (d, J = 16.9 Hz, 1H), 5.14 (dd, J = 10.1, 0.9 Hz, 1H), 3.70 (d, J = 9.6 Hz, 1H), 1.83 (dd, J = 14.2, 6.7 Hz, 1H), 1.74 (dd, J = 14.2, 5.9 Hz, 1H), 1.52 (dsep, J = 13.0, 6.5 Hz, 1H), 0.83 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 180.7, 159.6, 138.6, 135.2, 132.6, 129.1, 128.7, 128.4, 127.9, 127.3, 125.8, 118.9, 77.1, 58.5, 44.4, 25.0, 23.9, 23.3. HRMS (ESI) Calcd. for C₂₂H₂₄NO₂ ([M+H]⁺): 334.1802. Found: 334.1800.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	8.600	33554212	48.74	1692008	54.47
2	11.699	35286848	51.26	1414123	45.53

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	8.604	18482583	99.47	1215999	99.65
2	11.695	97653	0.53	4317	0.35

(S)-4-(2-(methylthio)ethyl)-2-phenyl-4-((R)-1-phenylallyl)oxazol-5(4H)-one




Prepared according to the general procedure using cinnamyl methyl carbonate (48.0 mg, 0.250 mmol), 4-methylthioethyl-2-phenyloxazol-5(4H)-one (129 mg, 0.550 mmol), $[\text{Ir}(\text{cod})\text{Cl}]_2$ (3.36 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 93% yield (81.6 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 6.21 min (major); t_R 8.53 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 98%. $[\alpha]_{D}^{25} = -71.8^\circ$ (c 4.1, CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3) δ 8.11 – 7.99 (m, 2H), 7.65 – 7.58 (m, 1H), 7.52 (t, $J = 7.6$ Hz, 2H), 7.49 – 7.43 (m, 2H), 7.35 (t, $J = 7.5$ Hz, 2H), 7.32 – 7.23 (m, 1H), 6.05 (dt, $J = 16.9, 9.9$ Hz, 1H), 5.23 (d, $J = 16.5$ Hz, 1H), 5.14 (dd, $J = 10.1, 1.2$ Hz, 1H), 3.74 (d, $J = 9.5$ Hz, 1H), 2.38 (ddd, $J = 12.5, 10.5, 4.5$ Hz, 1H), 2.30 (ddd, $J = 12.9, 10.4, 6.3$ Hz, 1H), 2.21 (ddd, $J = 13.9, 10.4, 6.3$ Hz, 1H), 2.01 (ddd, $J = 14.5, 10.4, 4.5$ Hz, 1H), 2.00 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 179.9, 160.6, 138.2, 135.0, 132.8, 129.1, 128.8, 128.5, 128.0, 127.5, 125.6, 119.2, 76.6, 57.5, 34.9, 28.6, 15.2. HRMS (ESI) Calcd. for $\text{C}_{21}\text{H}_{22}\text{NO}_2\text{S}$ ($[\text{M}+\text{H}]^+$): 352.1366. Found: 352.1364.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	6.210	30483752	47.99	1993724	52.39
2	8.534	33041950	52.01	1811519	47.61

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	6.222	37469676	99.14	2311017	99.06
2	8.581	324512	0.86	21861	0.94

(S)-4-benzyl-2-phenyl-4-((R)-1-phenylallyl)oxazol-5(4H)-one



Prepared according to the general procedure using cinnamyl methyl carbonate (48.0 mg, 0.250 mmol), 4-*iso*-propyl-2-phenyloxazol-5(4H)-one (112 mg, 0.550 mmol), [Ir(dbcot)Cl]₂ (4.32 mg, 0.0050 mmol), **1** (6.00 mg, 0.0100 mmol) and **2c** (11.6 mg, 0.0200 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 16:1 to 6:1) to give the title compound as colorless oil in 69% yield (55.0 mg). The enantiomeric excess was determined by HPLC analysis of methanolysis product (254 nm, 25 °C) t_R 15.94 min (major); t_R 14.13 min (minor) [(Chiralpak AD-H) hexane/i-PrOH, 98:2, 1.0 mL/min] to be 99%. [α]_D²⁵ = -50.3° (c 1.9, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.05 – 7.98 (m, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.52–7.47 (m, 4H), 7.34–7.27 (m, 2H), 7.26–7.21 (m, 1H), 6.14 (dt, J = 17.0, 9.8 Hz, 1H), 5.23 (d, J = 17.0 Hz, 1H), 5.14 (dd, J = 10.1, 1.1 Hz, 1H), 3.95 (d, J = 9.6 Hz, 1H), 2.19 (dsep, J = 13.6, 6.8 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 179.3, 159.8, 138.7, 135.7, 132.5, 129.2, 128.7, 128.3, 127.9, 127.2, 125.8, 118.4, 80.3, 54.3, 32.3, 16.7, 16.1. HRMS (ESI) Calcd. for C₂₁H₂₂NO₂ ([M+H]⁺): 320.1651. Found: 320.1645.




	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	13.877	10518464	51.42	361068	52.43
2	15.857	9936648	48.58	327615	47.57

	RT (min)	Area ($\mu\text{V}^*\text{sec}$)	% Area	Height (μV)	% Height
1	14.132	32722	0.45	1720	0.71
2	15.948	7267014	99.55	240490	99.29


Procedure for Synthesis of **6e**

(S)-4-((R)-1-(3,4-dichlorophenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one(**6b**)




Prepared according to the general procedure using 3,4-dichlorocinnamyl methyl carbonate **6a** (500 mg, 1.92 mmol), 4-methyl-2-phenyloxazol-5(4H)-one (740 mg, 4.22 mmol), [Ir(cod)Cl]₂ (25.8 mg, 0.0384 mmol), **1** (46.1 mg, 0.0768 mmol) and **2c** (89.1 mg, 0.154 mmol). The crude mixture was purified by flash column chromatography (hexanes:EtOAc, 6:1 to 3:1) to give the title compound **6b** as white wax in 93% yield (634 mg). $[\alpha]_D^{25} = -110^\circ$ (c 3.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.11 – 7.92 (m, 2H), 7.66 – 7.60 (m, 2H), 7.54 (t, *J* = 7.7 Hz, 2H), 7.45 (d, *J* = 8.3 Hz, 1H), 7.36 (dd, *J* = 8.3, 2.1 Hz, 1H), 5.90 (dt, *J* = 16.9, 9.9 Hz, 1H), 5.22 (d, *J* = 16.9 Hz, 1H), 5.15 (d, *J* = 10.0 Hz, 1H), 3.69 (d, *J* = 9.3 Hz, 1H), 1.38 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 180.0, 160.3, 138.6, 134.6, 132.9, 132.4, 131.5, 131.1, 130.4, 128.8, 128.6, 128.0, 125.5, 119.8, 73.1, 56.4, 22.4. HRMS (ESI) Calcd. for C₁₉H₁₇NO₂Cl₂ ([M+H]⁺): 360.0553. Found: 360.0552.

(2*S*,3*R*)-methyl 2-benzamido-3-(3,4-dichlorophenyl)-2-methylpent-4-enoate(**6c**)




(*S*)-4-((*R*)-1-(3,4-dichlorophenyl)allyl)-4-methyl-2-phenyloxazol-5(4H)-one **6b** (200 mg, 0.557 mmol) was dissolved in 10 mL methanol with anhydrous K₂CO₃ (20 mg, 0.144 mmol). The mixture was stirred for 1 h. After removing the solvent, the crude mixture was purified by flash column chromatography (hexanes:EtOAc, 6:1 to 2:1) to give the title compound **6c** as white wax in 95% yield (207 mg). The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) t_R 10.81 min (major); t_R 9.38 min (minor) [(Chiralpak AD-H) hexane/*i*-PrOH, 92.5:7.5, 1.0 mL/min] to be 94%. [α]_D²⁵ = +11.0° (c 0.9, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 7.73 – 7.66 (m, 2H), 7.53 (dd, *J* = 10.6, 4.2 Hz, 1H), 7.45 (t, *J* = 7.6 Hz, 2H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.23 (d, *J* = 2.1 Hz, 1H), 6.99 – 6.89 (m, 2H), 6.38 (dt, *J* = 16.8, 10.0 Hz, 1H), 5.44 (d, *J* = 16.9 Hz, 1H), 5.40 (dd, *J* = 10.1, 1.3 Hz, 1H), 4.35 (d, *J* = 10.0 Hz, 1H), 3.80 (s, 3H), 1.78 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 173.0, 166.4, 139.1, 134.9, 134.4, 132.4, 131.7, 131.5, 130.3, 130.2, 128.7, 127.8, 126.7, 120.5, 63.3, 54.4, 52.8, 19.8. HRMS (ESI) Calcd. for C₂₀H₂₀Cl₂NO₃ ([M+H]⁺): 392.0820. Found: 392.0814. Calcd. for C₂₀H₁₉Cl₂NO₃Na ([M+Na]⁺): 414.0640. Found: 414.0634.



	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	9.344	3030579	48.87	174036	51.62
2	10.796	3170224	51.13	163134	48.38


	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	9.379	170864	3.25	14223	5.09
2	10.812	5085635	96.75	265100	94.91

(2*S*,3*R*)-methyl 2-benzamido-3-(3,4-dichlorophenyl)-2-methyl-5-(tosyloxy)pentanoate(**6d**)




(*2S,3R*)-methyl 2-benzamido-3-(3,4-dichlorophenyl)-2-methylpent-4-enoate **6c** (50 mg, 0.128 mmole) was dissolved in dry, degassed THF (0.5 mL) and cooled to -78 °C. Then 9-BBN (0.56 mL as a 0.5 M solution in THF, 0.282 mmol) was added to the reaction vessel. The reaction mixture was stirred for 1 h at -78 °C, then allowed to warm slowly to room temperature and stirred overnight. The resulting solution was cooled to 0 °C, at which time water (1.0 mL), and NaBO₃·4H₂O (295 mg, 1.92 mmol) were added. The reaction was allowed to warm to room temperature and was stirred for an additional 6 h. The reaction mixture was diluted with DCM, and then extracted with DCM (3*3 mL). The organic layer was combined, dried over MgSO₄, filtered, and concentrated. The crude product was dissolved in DCM (1 mL) and cooled to 0 °C, at which time triethylamine (38.8 mg, 0.383 mmol) and TsCl (53.8 mg, 0.283 mmol) were added. The reaction was allowed to warm to room temperature and stirred for 1 h. The resulted solution was filtered through a 0.5 inch plug of silica gel (eluting with EtOAc) to remove the polar residue. After removing the solvent, the mixture was purified by flash column silica gel chromatography (hexanes:EtOAc, 6:1 to 2:1) to give the title compound **6d** as an colorless oil in 56% yield (40.4 mg). ¹H NMR (500 MHz, CDCl₃) δ 7.70 (d, *J* = 8.2 Hz, 2H), 7.66 (d, *J* = 7.2 Hz, 2H), 7.53 (t, *J* = 7.4 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.25 (d, *J* = 8.3 Hz, 1H), 7.01 (d, *J* = 1.9 Hz, 1H), 6.87 (s, 1H), 6.80 (dd, *J* = 8.3, 1.9 Hz, 1H), 3.99 (ddd, *J* = 10.7, 6.7, 4.0 Hz, 1H), 3.86 – 3.78 (m, 4H), 3.70 (td, *J* = 9.5, 5.6 Hz, 1H), 2.56 – 2.44 (m, 4H), 2.28 – 2.19 (m, 1H), 1.84 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 172.9, 166.8, 145.0, 138.0, 134.5, 132.5, 132.4, 131.8, 131.7, 130.5, 130.3, 129.8, 128.6, 127.8, 126.7, 68.2, 63.9, 52.9, 46.1, 29.3, 21.7, 21.2.


(*2S,3R*)-methyl 1-benzoyl-3-(3,4-dichlorophenyl)-2-methylpyrrolidine-2-carboxylate(**6e**)



(*2S,3R*)-methyl 2-benzamido-3-(3,4-dichlorophenyl)-2-methyl-5-(tosyloxy)pentanoate **6d** (20mg, 0.0355 mmol) and NaH (1.35 mg, 0.0563 mmol) were dissolved in dry DMF (0.5 mL). The mixture was stirred for 12 h at room temperature. After removing the solvent in vacuum, the mixture was purified by flash column silica gel chromatography (hexanes:EtOAc, 6:1 to 3:1) to give the title compound **6e** as an colorless oil in 95% yield (13.2 mg). ¹H NMR (500 MHz, CDCl₃) δ 7.52-7.48 (m, 2H), 7.47 – 7.37 (m, 4H), 7.24 (d, *J* = 1.8 Hz, 1H), 6.97 (dd, *J* = 8.3, 1.8 Hz, 1H), 3.86 (s, 3H), 3.79 (td, *J* = 10.8, 6.2 Hz, 1H), 3.72 (dd, *J* = 12.9, 5.6 Hz, 1H), 3.70 – 3.64 (m, 1H), 2.49-2.35 (m, 1H), 2.30 – 2.18 (m, 1H), 1.31 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 173.8, 169.1, 136.6, 136.6, 132.6, 131.8, 130.4, 130.1, 129.8, 128.4, 127.8, 126.5, 68.7, 52.7, 51.5, 48.8, 28.3, 16.7. HRMS (ESI) Calcd. for C₂₀H₁₉NO₃Na ([M+Na]⁺): 414.0640. Found: 414.0633.

1. Melhado, A. D.; Luparia, M.; Toste, F. D. *J. Am. Chem. Soc.* **2007**, *129*, 12638.
2. Stanley, L. M.; Hartwig, J. F. *Angew. Chem., Int. Ed.* **2009**, *48*, 7841.
3. Polet, D.; Alexakis, A.; Tissot-Croset, K.; Corminboeuf, C.; Ditrich, K. *Chem. -Eur. J.* **2006**, *12*, 3596.
4. Stanley, L. M.; Hartwig, J. F. *J. Am. Chem. Soc.* **2009**, *131*, 8971.
5. Chaffins, S.; Brettreich, M.; Wudl, F. *Synthesis* **2002**, 1191.
6. Wuennemann, S.; Froehlich, R.; Hoppe, D. *Eur. J. Org. Chem.* **2008**, 684.





-180.612


-159.814


138.348
135.522
132.655
129.132
128.725
128.467
127.948
127.373
125.823
118.861


-73.482


-57.541



-22.429

















9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0

f1 (ppm)

S29





-180.689


159.749
158.798

135.721
132.604
130.411
130.125
128.703
127.929
125.871
118.494
113.840

-73.570


56.692
55.188


-22.404



f1 (ppm)

S31





-180.223



-160.216
142.510
134.790
132.921
129.784
129.618
129.527
128.846
128.023
125.632
125.475
125.446
125.416
125.217
123.055
119.748


-73.243


-57.143

-22.454

190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)







-179.864



-160.409



147.269
146.020
134.182
133.071
130.157
128.901
128.038
125.446
123.717
120.329


-73.029



-57.028


-22.511














-179.671

-160.209


-151.730


-141.865
132.681
132.656
128.696
127.957
125.725
119.666
110.387
~107.834


-72.521



-50.922


-22.362

























-180.708

-159.667


138.625
135.217
132.617
129.187
128.785
128.439
127.932
127.310
125.872
118.963


-77.155

-58.531


-44.492


25.038
23.962
23.331








crude NMR
















crude NMR
















—146.892
—139.604
—139.572
—130.736
—126.455
—124.726



35.477
34.627
31.516
31.461





















7.516
7.512
7.503
7.497
7.443
7.439
7.422
7.280
7.239
7.236
6.982
6.978
6.965
6.961
3.864
3.813
3.801
3.792
3.779
3.770
3.758
3.743
3.732
3.718
3.706
3.687
3.679
3.670
3.651



1.97
4.24
1.05
1.00



2.92
3.38

1.24
1.27

3.55

16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3 -4

f1 (ppm) S65



[Ir(cod)Cl]2 + 1 + 2c + methyl cinnamyl carbonate

PPh3 internal standard

